These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 21440531)

  • 1. Validation of experimental medicine methods in psychiatry: the P1vital approach and experience.
    Dawson GR; Craig KJ; Dourish CT
    Biochem Pharmacol; 2011 Jun; 81(12):1435-41. PubMed ID: 21440531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. From biomarker strategies to biomarker activities and back.
    van Gool AJ; Henry B; Sprengers ED
    Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Developing predictive CSF biomarkers-a challenge critical to success in Alzheimer's disease and neuropsychiatric translational medicine.
    Flood DG; Marek GJ; Williams M
    Biochem Pharmacol; 2011 Jun; 81(12):1422-34. PubMed ID: 21295552
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Special issue on CNS experimental medicine.
    Dawson GR; Dourish CT; Goodwin GM
    J Psychopharmacol; 2011 Sep; 25(9):1145-7. PubMed ID: 21994313
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative psychology and the grand challenge of drug discovery in psychiatry and neurodegeneration.
    Brunner D; Balcı F; Ludvig EA
    Behav Processes; 2012 Feb; 89(2):187-95. PubMed ID: 22155361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A translational research framework for enhanced validity of mouse models of psychopathological states in depression.
    Pryce CR; Seifritz E
    Psychoneuroendocrinology; 2011 Apr; 36(3):308-29. PubMed ID: 20538414
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NCI All Ireland Cancer Conference.
    Johnston PG; Daly PA; Liu E
    Oncologist; 1999; 4(4):275-277. PubMed ID: 10545862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The analysis of physicians' work: announcing the end of attempts at in vitro fertilization].
    Santiago-Delefosse M; Cahen F; Coeffin-Driol C
    Encephale; 2003; 29(4 Pt 1):293-305. PubMed ID: 14615699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Animal models of CNS disorders.
    McGonigle P
    Biochem Pharmacol; 2014 Jan; 87(1):140-9. PubMed ID: 23811310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is pharma running out of brainy ideas?
    Miller G
    Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165
    [No Abstract]   [Full Text] [Related]  

  • 12. Aligning strategies for using EEG as a surrogate biomarker: a review of preclinical and clinical research.
    Leiser SC; Dunlop J; Bowlby MR; Devilbiss DM
    Biochem Pharmacol; 2011 Jun; 81(12):1408-21. PubMed ID: 20937262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive design clinical trials and trial logistics models in CNS drug development.
    Wang SJ; Hung HM; O'Neill R
    Eur Neuropsychopharmacol; 2011 Feb; 21(2):159-66. PubMed ID: 20933373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NIH Roundtable on Opportunities to Advance Research on Neurologic and Psychiatric Emergencies.
    D'Onofrio G; Jauch E; Jagoda A; Allen MH; Anglin D; Barsan WG; Berger RP; Bobrow BJ; Boudreaux ED; Bushnell C; Chan YF; Currier G; Eggly S; Ichord R; Larkin GL; Laskowitz D; Neumar RW; Newman-Toker DE; Quinn J; Shear K; Todd KH; Zatzick D;
    Ann Emerg Med; 2010 Nov; 56(5):551-64. PubMed ID: 21036295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CNS drug development: part III: future directions.
    Preskorn SH
    J Psychiatr Pract; 2011 Jan; 17(1):49-52. PubMed ID: 21266894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging science, emerging ethical issues: who should fund innate alloimmunity-suppressing drugs?
    Land WG; Gutmann T; Daar AS
    Acta Chir Belg; 2008; 108(1):73-82. PubMed ID: 18411578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.